Study of the use possibility of the chemical-biological adduct of the 1,1-bis-[5-bromopyrimidine-2’,4’-diono-1’-il]-2-bromo-2’-chloroethylene and bacterial lectin for the treatment of the Pliss’ lymphosarcoma
Aim. Study of the pyrimidine metabolism antimetabolites that can be preformed compounds in the link of biosynthetic processes and can brake tumour’s growth is a more successful, perspective finding direction of new antitumor medications. New original chemical-biological adduct was studied as potenti...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporozhye State Medical University
2015-04-01
|
| Series: | Zaporožskij Medicinskij Žurnal |
| Subjects: | |
| Online Access: | http://zmj.zsmu.edu.ua/article/view/42048/38339 |
| Summary: | Aim. Study of the pyrimidine metabolism antimetabolites that can be preformed compounds in the link of biosynthetic processes and can brake tumour’s growth is a more successful, perspective finding direction of new antitumor medications. New original chemical-biological adduct was studied as potential antitumor agent.
Methods and results. It was obtained on the base of 1,1-bis-[5-bromopyrimidine-2’,4’-diono-1’-il]-2-bromo-2’-chloroethylene and antitumour bacterial lectin from Bacillus polymyxa. It was found that new chemical-biological adduct of bis-derivative of pyrimidine and bacterial lectin has little toxic preparation (LD50=635 mg/kg) and demonstrates considerable antitumour effect upon to 65.5% on Pliss Limphosarcoma tumour.
Conclusion. It confirms that new chemical-biological adduct is perspective for the future investigation as substance with a little toxicity and high antitumour activity on the Pliss Limphosarcoma. |
|---|---|
| ISSN: | 2306-4145 2310-1210 |